Actively Recruiting
Phase IbII Open-label Study of Intrathecal S230815 in Children with KCNT1-related Developmental and Epileptic Encephalopathy
Led by Institut de Recherches Internationales Servier · Updated on 2026-10-13
20
Participants Needed
15
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamic effects of the drug S230815 in children aged 2 to 12 years with Developmental Epileptic Encephalopathy caused by a specific genetic variant in the KCNT1 gene. This first-in-human, open-label study includes pediatric participants with genetically confirmed disease and aims to understand how the drug behaves in the body and its effects on seizure frequency. The study consists of a screening period followed by two parts Part 1 involves testing multiple ascending doses of S230815 to find appropriate dosing levels. Part 2 is a long-term treatment extension where participants who finish Part 1 continue receiving S230815 for up to 72 weeks, staying in the same dosing group assigned initially. The drug is given as a solution for injection. Participants will be closely monitored throughout the study with assessments including recording seizures through daily logs and video electroencephalogram vEEG, blood and cerebrospinal fluid tests to study drug levels, and safety evaluations for adverse events. The total study duration can be up to 116 weeks, including long-term follow-up to observe effects and safety. Researchers also track use of rescue medications and other clinical measures related to epilepsy.
CONDITIONS
Brief Title
A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy
Research Team
I
Institut de Recherches Internationales Servier
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here